Does Medicare cover Zepbound?
The short answer
Medicare Part D doesn't cover Zepbound for weight loss, but the Medicare GLP-1 Bridge does for eligible enrollees from July 1, 2026 through December 31, 2027: $50 per month, for the KwikPen only. Single-dose vials and single-dose pens aren't included. According to CMS, Part D can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity.
Key takeaways
- Part D doesn't cover Zepbound for weight loss.
- If you're eligible, the Medicare GLP-1 Bridge covers only the KwikPen, for $50 per one-month supply, not vials or single-dose pens.
- Part D can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, through your plan.
- That sleep apnea diagnosis makes you ineligible for the Bridge, even if your plan doesn't cover a GLP-1 for it.
- The Bridge doesn't cover pen needles, so you buy them separately.
On this page
- The short version
- Why Part D will not pay for Zepbound for weight loss
- The Bridge covers the KwikPen only
- Who qualifies for Zepbound through the Bridge
- Sleep apnea: a Part D route, and a Bridge exclusion
- What about Mounjaro?
- After 2027
- If no Medicare route applies
- What to ask, and whom
- Frequently asked questions
- Sources
Medicare’s coverage of Zepbound has two quirks the other GLP-1s don’t share. For weight management, the temporary Bridge program covers only one of Zepbound’s forms. And Zepbound’s sleep apnea use opens a route through Part D, Medicare’s drug coverage, while closing the Bridge one. This page explains both. It belongs to our Medicare and GLP-1 guide. Prices outside Medicare are on the Zepbound cost page.
The short version
- Zepbound for weight management: not covered by Part D. Eligible Part D enrollees can get the KwikPen through the Medicare GLP-1 Bridge for $50 per one-month supply until December 31, 2027.
- Zepbound vials and single-dose pens: not covered by the Bridge at all.
- Zepbound for moderate to severe obstructive sleep apnea in adults with obesity: coverable by Part D, through your plan.
Why Part D will not pay for Zepbound for weight loss
The Part D statute excludes “agents when used for anorexia, weight loss, or weight gain” from the definition of a covered Part D drug. CMS’s long-standing policy is that an anti-obesity medication is coverable in Part D only when it’s used for another medically accepted indication. Zepbound’s label has two uses: weight reduction, which falls under the exclusion, and obstructive sleep apnea, which doesn’t.
The Bridge covers the KwikPen only
The Medicare GLP-1 Bridge is a CMS demonstration running from July 1, 2026 through December 31, 2027. For Zepbound, CMS’s wording is exact: the KwikPen formulation is available, and the single-dose vial and single-dose pen formulations are not.
That has practical effects.
Your prescription has to be for the KwikPen. The KwikPen is a single-patient-use pen that holds a month of weekly doses. If you’ve been using vials bought through LillyDirect, or single-dose pens through a commercial plan before you joined Medicare, the Bridge won’t pay for those forms. Ask your prescriber about a KwikPen prescription.
Pen needles are extra. CMS says pen needles aren’t covered by the Bridge and should not be billed to the Bridge or to your Part D plan. You buy them separately.
The copay is flat. It’s $50 for a one-month supply, whatever the dose. For comparison, the same KwikPen costs $299 to $449 a month through LillyDirect self-pay, depending on dose. The Bridge copay doesn’t count toward your Part D deductible or out-of-pocket limit, Extra Help doesn’t reduce it, and coupons can’t be applied.
One fill at a time. Each fill is a single monthly supply. There are no 60-day or 90-day fills, and no override for lost or stolen medication.
Who qualifies for Zepbound through the Bridge
You must be 18 or older, enrolled in an eligible Part D plan, and prescribed Zepbound to reduce excess body weight and maintain the reduction, alongside lifestyle modification with structured nutrition and physical activity.
You must also meet one BMI tier, measured at the time you first started GLP-1 therapy:
- BMI 35 or higher
- BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above
- BMI 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease
The BMI that counts is your starting BMI. So if you began Zepbound before joining Medicare and have since lost weight, you’re judged on the earlier figure. CMS says the criteria apply at therapy initiation, including for people who started before enrolling in Part D or before the Bridge launched.
You’re not eligible if your Part D plan has paid for a GLP-1 in 2026, or if you have type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH. The Bridge explainer covers each rule, and the eligibility checker applies them to you.
Your prescriber completes one prior authorization (the approval that lets the fill go through). Once approved, it’s valid for refills and dose changes through December 31, 2027. Zepbound’s label steps the dose up over several months, and those changes don’t need a new approval.
Sleep apnea: a Part D route, and a Bridge exclusion
CMS gives Zepbound for the treatment of moderate to severe obstructive sleep apnea in adults with obesity as an example of a use that’s coverable under the basic Part D benefit, whether or not Zepbound is on the plan’s formulary (its list of covered drugs). Plans must keep following their formulary exception processes for these requests.
Two things follow.
First, if you have that diagnosis, your route is your Part D plan. Your prescriber may need to submit a prior authorization or formulary exception, and the plan decides under its own rules. The KwikPen-only limit is a Bridge rule. Which Zepbound forms your Part D plan will pay for is a question for the plan.
Second, the diagnosis shuts the Bridge. CMS says a person with moderate to severe obstructive sleep apnea isn’t eligible for the Bridge, whether or not their current Part D plan covers a GLP-1 for that condition. You can’t choose the Bridge because its copay looks better.
Under Part D, the cost follows the standard benefit: a deductible of no more than $615 in 2026, then coinsurance until your out-of-pocket spending on covered Part D drugs reaches $2,100, then nothing more for covered drugs that year. Whether that works out higher or lower than the Bridge copay over a year depends on your plan and the other drugs you take. See Part D costs in 2026.
What about Mounjaro?
Mounjaro contains tirzepatide, like Zepbound, and is a separate product for type 2 diabetes. It isn’t on the Bridge’s list of covered products. CMS says type 2 diabetes is an indication eligible for Part D coverage, so a Mounjaro prescription for diabetes goes through your Part D plan, and a type 2 diabetes diagnosis makes you ineligible for the Bridge. The Mounjaro page has more on that medicine.
After 2027
CMS hasn’t said what Medicare coverage of Zepbound for weight management will look like after December 31, 2027. One detail in the record points the same way as the Bridge: the drugs included in the BALANCE Model, the longer-term CMS model that hasn’t launched in Medicare, list the KwikPen formulation of Zepbound and not the other forms. The BALANCE Model page has more on that model.
If no Medicare route applies
If you don’t meet the Bridge criteria and don’t have a sleep apnea diagnosis, Medicare won’t pay for Zepbound, and the Lilly savings card excludes Medicare enrollees. That leaves paying cash. LillyDirect’s self-pay prices for vials and the KwikPen are on the Zepbound cost page. No insurance is used, and the higher-dose prices depend on refilling within 45 days.
What to ask, and whom
- Your prescriber: what is Zepbound being prescribed for, what was my BMI when I started GLP-1 therapy, and can the prescription be written for the KwikPen?
- Your pharmacy: for a weight-management prescription, ask them to send the claim to the Medicare GLP-1 Bridge. They don’t need a denial from your Part D plan first.
- Your Part D plan: for a sleep apnea prescription, ask about the formulary, the tier and the exception process.
- Medicare: if you’re not sure what type of plan you have, call 1-800-MEDICARE (1-800-633-4227).
Frequently asked questions
How much is Zepbound with Medicare?
For weight management through the Medicare GLP-1 Bridge, it's $50 per one-month supply of the KwikPen if you meet the criteria. Pen needles aren't covered, so you buy them separately. For sleep apnea through Part D, the cost depends on your plan's deductible, tier and coinsurance, up to the $2,100 out-of-pocket cap on covered Part D drugs in 2026.
Does the Medicare Bridge cover Zepbound vials?
No. CMS says the single-dose vial and single-dose pen formulations of Zepbound will not be available through the Medicare GLP-1 Bridge. Only the KwikPen formulation is covered. If your prescription is written for vials or the single-dose pen, your prescriber would need to write a KwikPen prescription for the Bridge to apply.
Does Medicare cover Zepbound for sleep apnea?
Part D can. CMS names Zepbound for the treatment of moderate to severe obstructive sleep apnea in adults with obesity as a use coverable under the basic Part D benefit, whether or not the drug is on your plan's formulary. Plans handle these requests through their formulary exception process. A sleep apnea diagnosis also makes you ineligible for the Bridge.
I have sleep apnea and want Zepbound for weight loss. Can I use the Bridge?
No. CMS says a beneficiary with a diagnosis of moderate to severe obstructive sleep apnea isn't eligible for the Bridge, whether or not their current Part D plan covers a GLP-1 for that condition. Because sleep apnea is an indication eligible for Part D coverage, the request goes to your Part D plan instead.
Can I use the Zepbound savings card or LillyDirect with Medicare?
The savings card, no: Lilly's terms exclude anyone enrolled in Medicare, Medicare Part D or Medicare Advantage. LillyDirect self-pay is a cash program in which no insurance is used and the cost can't be reimbursed. Zepbound starts at $299 a month there. Check the Bridge and Part D first, since the Bridge copay is far lower.
Sources (10)
- 1.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 2.CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
“Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
- 3.CMS: Information for Part D Plans
“Beneficiaries who are prescribed an eligible GLP-1 drug for a use that is coverable under the basic Medicare Part D benefit, regardless of whether the eligible GLP-1 drug is on the Part D plan’s formulary (e.g., Zepbound® for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity; Wegovy® to reduce the risk of major adverse cardiovascular (CV) events in adults with established CV disease and either obesity or overweight) would not qualify for coverage of that eligible GLP-1 drug under the Medicare GLP-1 Bridge. Part D plan sponsors must continue to follow their existing formulary exception processes for these requests.”
- 4.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 5.Medicare.gov: How much does Medicare drug coverage cost?
“After you reach your full deductible (if your plan has a deductible), you’ll pay 25% of the cost as coinsurance for your generic and brand-name drugs until your out-of-pocket spending on covered Part D drugs reaches $2,100 in 2026 ($2,400 in 2027)(including certain payments made on your behalf, like through the Extra Help program). Then, you’ll automatically get “catastrophic coverage.” Catastrophic coverage stage: You won’t have to pay out-of-pocket for covered Part D drugs for the rest of the calendar year.”
- 6.Medicare.gov: How much does Medicare drug coverage cost?
“No Medicare drug plan may have a deductible more than $615 in 2026 ($700 in 2027). Some Medicare drug plans don’t have a deductible.”
- 7.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“All formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy®, the KwikPen formulation of Zepbound®, and Foundayo™. These are included for both currently covered indications (ex: type 2 diabetes) as well as weight management indications.”
- 8.
- 9.
- 10.
